Table Info

Table 4.

Comparison of mean visfatin levels (ng/mL) between the obese and non-obese groups

Time	Group	N	Mean	SD	SEM	t-value	p-value
Baseline	Obese	20	17.73	0.90	0.20	15.30	< 0.05*
Baseline	Non-obese	20	13.06	1.02	0.22	15.30	< 0.05*
6 weeks	Obese	20	16.76	0.84	0.18	16.40	< 0.05*
6 weeks	Non-obese	20	12.01	0.98	0.21	16.40	< 0.05*

Independent samples t-test; p < 0.05 considered statistically significant; *: denotes significance

Declarations

Author contributions

AP: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing—original draft, Resources. AD: Conceptualization, Project administration, Supervision, Validation, Visualization, Writing—original draft, Writing—review & editing. RD: Conceptualization, Project administration, Supervision, Validation, Visualization, Writing—original draft, Writing—review & editing. KKK: Conceptualization, Supervision, Validation, Visualization. RB: Writing—original draft, Validation, Visualization, Writing—review & editing. TP: Conceptualization, Project administration, Supervision, Validation, Visualization.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This study was approved by the SIBAR Institutional Ethical Committee (approval reference number: Pr.36/IEC/SIBAR/2021) and was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. All participants provided informed consent prior to their involvement, ensuring they were fully informed about the purpose, procedures, and potential risks of the study.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The data that support the findings of this study are not publicly available due to privacy concerns and the confidential nature of participant information. In order to protect the privacy of the individuals involved, the data will remain confidential and will not be shared publicly.

Funding

Not applicable.

Copyright

References

Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol. 1999;4:1–6. [DOI] [PubMed]

Listgarten MA. Pathogenesis of periodontitis. J Clin Periodontol. 1986;13:418–30. [DOI] [PubMed]

Saito T, Shimazaki Y. Metabolic disorders related to obesity and periodontal disease. Periodontol 2000. 2007;43:254–66. [DOI] [PubMed]

Dahiya P, Kamal R, Gupta R. Obesity, periodontal and general health: Relationship and management. Indian J Endocrinol Metab. 2012;16:88–93. [DOI] [PubMed] [PMC]

Saito T, Shimazaki Y, Sakamoto M. Obesity and periodontitis. N Engl J Med. 1998;339:482–3. [DOI] [PubMed]

Boyapati R, Chintalapani S, Ramisetti A, Salavadhi SS, Ramachandran R. Evaluation of Serum Leptin and Adiponectin in Obese Individuals with Chronic Periodontitis. Contemp Clin Dent. 2018;9:S210–4. [DOI] [PubMed] [PMC]

Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911–9; quiz 920. [DOI] [PubMed]

Chaffee BW, Weston SJ. Association between chronic periodontal disease and obesity: a systematic review and meta-analysis. J Periodontol. 2010;81:1708–24. [DOI] [PubMed] [PMC]

Kandhan TS, Rajasekar A. Prevalence of periodontal diseases among patients with and without systemic diseases—A retrospective study. J Complement Med Res. 2020;11:155–62. [DOI]

10.

Giannobile WV, Beikler T, Kinney JS, Ramseier CA, Morelli T, Wong DT. Saliva as a diagnostic tool for periodontal disease: current state and future directions. Periodontol 2000. 2009;50:52–64. [DOI] [PubMed] [PMC]

11.

Ceylan Şen S, Özcan E, Saygun N, Özgürtaş T, Azızov R. Evaluation of salivary visfatin, leptin and oxidative stress markers in obese and non-obese periodontitis patients. ADO Klinik Bilimler Dergisi. 2022;11:270–9. [DOI]

12.

Isola G, Polizzi A, Santonocito S, Alibrandi A, Pesce P, Kocher T. Effect of quadrantwise versus full-mouth subgingival instrumentation on clinical and microbiological parameters in periodontitis patients: A randomized clinical trial. J Periodontal Res. 2024;59:647–56. [DOI] [PubMed]

13.

Çetiner D, Uraz A, Öztoprak S, Akça G. The role of visfatin levels in gingival crevicular fluid as a potential biomarker in the relationship between obesity and periodontal disease. J Appl Oral Sci. 2019;27:e20180365. [DOI] [PubMed] [PMC]

14.

Waist circumference and waist-hip ratio: report of a WHO expert consultation [Internet]. Geneva: World Health Organization; c2024 [cited 2024 Oct 31]. Available from: https://www.who.int/publications/i/item/9789241501491

15.

Löe H. The Gingival Index, the Plaque Index and the Retention Index Systems. J Periodontol. 1967;38:610–6. [DOI] [PubMed]

16.

Isidor F, Karring T, Attström R. Reproducibility of pocket depth and attachment level measurements when using a flexible splint. J Clin Periodontol. 1984;11:662–8. [DOI] [PubMed]

17.

Keller A, Rohde JF, Raymond K, Heitmann BL. Association between periodontal disease and overweight and obesity: a systematic review. J Periodontol. 2015;86:766–76. [DOI] [PubMed]

18.

Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol. 2008;83:804–16. [DOI] [PubMed]

19.

Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, et al. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int. 2007;80:201–10. [DOI] [PubMed]

20.

Gosset M, Berenbaum F, Salvat C, Sautet A, Pigenet A, Tahiri K, et al. Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis Rheum. 2008;58:1399–409. [DOI] [PubMed]

21.

Bae Y, Bae M, Kim S, Lee JH, Wee H, Bae S. Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. Biochem Biophys Res Commun. 2009;379:206–11. [DOI] [PubMed]

22.

Duan JY, Ou-Yang XY, Zhou YX. Effect of periodontal initial therapy on the serum level of lipid in the patients with both periodontitis and hyperlipidemia. J Peking Univ Health Sci. 2009;41:36–9. Chinese. [PubMed]

23.

Fentoğlu O, Sözen T, Oz SG, Kale B, Sönmez Y, Tonguç MO, et al. Short-term effects of periodontal therapy as an adjunct to anti-lipemic treatment. Oral Dis. 2010;16:648–54. [DOI] [PubMed]

24.

Zuza EP, Barroso EM, Fabricio M, Carrareto ALV, Toledo BEC, Pires JR. Lipid profile and high-sensitivity C-reactive protein levels in obese and non-obese subjects undergoing non-surgical periodontal therapy. J Oral Sci. 2016;58:423–30. [DOI] [PubMed]

25.

Tabari ZA, Azadmehr A, Nohekhan A, Naddafpour N, Ghaedi FB. Salivary visfatin concentrations in patients with chronic periodontitis. J Periodontol. 2014;85:1081–5. [DOI] [PubMed]

26.

Abolfazli N, Jabali S, Saber FS, Babaloo Z, Shirmohammadi A. Effect of Non-surgical Periodontal Therapy on Serum and Salivary Concentrations of Visfatin in Patients with Chronic Periodontitis. J Dent Res Dent Clin Dent Prospects. 2015;9:11–7. [DOI] [PubMed] [PMC]

27.

Fu YW, Li XX, Xu HZ, Gong YQ, Yang Y. Effects of periodontal therapy on serum lipid profile and proinflammatory cytokines in patients with hyperlipidemia: a randomized controlled trial. Clin Oral Investig. 2016;20:1263–9. [DOI] [PubMed]

28.

Kumar V, Amrita, Pratap M, Sharma S, Singh K, Saimbi CS. Evaluation of salivary levels of visfatin in obese patients with chronic periodontitis. Indian J Dent Sci. 2019;11:20–4. [DOI]

29.

Coutinho A, Reddy N, Chatterjee A, Khan MI. The Role of Visfatin (Adipocytokine) Biomarker in Oral Health and Diseases among Nonobese Indian Population: A Proteomic Assay. Glob Med Genet. 2021;8:104–8. [DOI] [PubMed] [PMC]

30.

Rajasekar A. Correlation of salivary visfatin levels in obese and Non-Obese population with periodontal status. J Oral Biol Craniofac Res. 2023;13:67–70. [DOI] [PubMed] [PMC]